NY-ESO-1 TCR/IL-15 NK

N/A

Report date: 2023/10/23 20:07:51
First In Class

Base Information

Drug NameNY-ESO-1 TCR/IL-15 NK
Drug Alias NameNY ESO1 TCR/IL15 NK (Syena/MD Anderson Cancer Center)NY-ESO-1 TCR/IL-15 Cell (Syena/MD Anderson Cancer Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derived
Mechanisms of ActionNY-ESO-1 gene transferenceInterleukin-15 modulators
TargetsCancer/testis antigen 1Interleukin-15
Therapy Area/IndicationsMultiple MyelomaSarcoma, SynovialLiposarcoma, Myxoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesReplay Holdings LLCThe University Of Texas MD Anderson Cancer CenterSyena
China Registration ClassN/A

Develop Information

Active CompaniesReplay Holdings LLCThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaSarcoma, SynovialLiposarcoma, Myxoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A